Please login to the form below

Not currently logged in
Email:
Password:

gene-editing

This page shows the latest gene-editing news and features for those working in and with pharma, biotech and healthcare.

Gilead study resurrects HIV eradication hope

Gilead study resurrects HIV eradication hope

Researchers are looking at other ways to eradicate HIV, including gene-editing techniques which focus on snipping HIV genetic material from cells or rendering immune cells resistant to entry by the

Latest news

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Gene therapy Gene therapy

    the promise of gene therapy in the early nineties could not be remotely met. ... From a payload perspective, these include new technologies such as siRNA, Sleeping Beauty transposases, CRISPR-Cas9 gene editing, ARCUS gene editing, nucleic acid vaccines,

  • Deal Watch March 2017 Deal Watch March 2017

    Editas Medicine has entered a strategic R&D alliance where Allergan has exclusive access to Editas’s CRISPR genome-editing programmes in ocular health, as well as options to license up ... 100. Editas. Allergan. R&D alliance. LCA10 and up to four other

  • Winning the war against cancer Winning the war against cancer

    areas such as the gene-editing CRISPR technology.

  • Deal Watch May 2016 Deal Watch May 2016

    disease late last year, Bayer announced another gene editing pact this month with ERS Genomics. ... 5, 200. Univ Pennsylvania/ Biogen. Licence. Gene editing and therapy using AAV vectors; $20m upfront, $62.5m in R&D funds, $77.5 -$137.5m m/s per programme

  • Deal Watch December 2015 Deal Watch December 2015

    350. CRISPR Therapeutics (CH). Bayer Lifescience. Joint venture. Combining gene editing technology and protein engineering to discover treatments for blood disorders, blindness, congenital heart disease.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Eric Rhodes becomes CEO of ERS Genomics Eric Rhodes becomes CEO of ERS Genomics

    In these roles, Rhodes was responsible for commercialising the company's genome editing technologies as well as driving its research and development. ... Biosciences. Foy said: “ With his deep understanding of the gene-editing landscape and extensive

  • Marc Becker joins CRISPR Therapeutics Marc Becker joins CRISPR Therapeutics

    Marc Becker joins CRISPR Therapeutics. He becomes chief financial officer. CRISPR Therapeutics has appointed Marc Becker as its new chief financial officer with remit to drive development of its gene-editing

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Perspective on biotech

    Find out about:. The emerging technologies revolutionising the biotech industry – from immunotherapy breakthroughs to cutting-edge gene editing techniques.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics